RxDoctor Payments Data

Norberto Torres-Otero, MD

Internal Medicine · White Plains, NYNPI 1174508139

Payments from drug & device makers

$2,410in general payments, 2019–2025

Across 71 payments — averaging $33.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$720
  • Novo Nordisk$300
  • Amgen$299
  • Takeda Pharmaceuticals U.S.A., Inc.$246
  • Exact Sciences$184
  • QOL Medical, LLC$165
  • plus $497 from 10 others

What the payments were for

  • Food & beverage$2,410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,410 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$50,737
Medicare patients
175
Services billed
643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol43$43,445
OzempicSemaglutide28$30,703
EliquisApixaban17$25,615
JardianceEmpagliflozin13$18,728
LinzessLinaclotide12$16,282
EntrestoSacubitril/Valsartan16$15,405
XareltoRivaroxaban11$7,635
Metoprolol Succinate217$3,427
Albuterol Sulfate HfaAlbuterol Sulfate62$3,402
Fluticasone Propionate138$2,859
Atorvastatin Calcium295$2,627
Omeprazole129$2,543
Rosuvastatin Calcium158$2,449
Ibuprofen124$2,053
Oxycodone Hcl81$1,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$720$43,44543 claims
Novo NordiskOzempic$300$30,70328 claims
Boehringer IngelheimJardiance$121$18,72813 claims
AbbVieLinzess$49$16,28212 claims
NovartisEntresto$154$15,40516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →